CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD

Size: px
Start display at page:

Download "CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD"

Transcription

1 CALIBRATION OF ANALYTICAL STANDARDS FOR HBV-DNA, HCV-RNA AND HIV-1 RNA IN GENOME COPIES BY A REFERENCE METHOD AAJ van Drimmelen, E.R. Bax and W.G.V. Quint, BioQControl (BQC), Delft Diagnostic Laboratories (DDL), Voorburg, the Netherlands Background Accurate quantification of analytical standards for viral nucleic acid tests (NAT) and estimation of the 50% minimum infectious dose in virion numbers and nucleic acid copies is essential for determining the risk of virus transmission by NAT screened blood donations (Weusten et al, Transfusion 2002, 42; ). The WHO international standards are useful in providing inter-laboratory comparability and common quantification in assigned International Units (IU's), which is the 4 th metrological level. The continuity of international units is based on collaborative studies involving different laboratories and a variety of assays. The relation between IU and genome copies, the SI unit, differs per assay and enhances the uncertainty with recalibrating replacements standards in IU. Calibration of standards in SI units provides a system traceable to the first metrological level (ISO 17511; 2003) but the required reference method for quantifying viral standards in nucleic acid copies has not been established. The calibrators in the historical Chiron Quantiplex bdna assay have been quantified in genome copies by physico-chemical techniques (Collins et al, Analytical Biochemistry, 226, ). Therefore the current Versant bdna 3.0 assays (Siemens) may serve as a reference method for quantification of viral plasma standards in copies/ml. Aims To quantify HBV genotype A, HCV genotype 1 and HIV 1 group M subtype B viral plasma standards in copies/ml using available bdna 3.0 test results from different studies and to determine the conversion factors from historically assigned genome equivalents (geq) to bdna 3.0 copies and IUs. Methods Our database includes quantitative and qualitative test results of proficiency studies, WHO standardization studies and validation studies of NAT blood screening assays. After initial assessment of the quantitative results of a variety of viral load assays the bdna 3.0 assay results were used to requantify the WHO and BQC standards in copies/ml. Finally the 63% detection endpoint of NAT screening assays was expressed in the newly assigned copy numbers in order to compare the viral concentration at a theoretical input level of one viral copy per amplification assay according to Poisson distribution. Results The quantification of the BQC and WHO standards in copies/ml according to bdna 3.0 assay is presented in table 1. The previous quantification in geq/ml is included for comparison. The conversion factors from historical geq to copies were 2.38, 1.40 and 1.39 for HIV-RNA, HBV-DNA and HCV-RNA respectively, whereas the conversion factors from IU to copies were 0.48, 5.33 and 2.73 respectively. Limiting dilution analysis on the Ampliscreen and Taqscreen results (table 2) revealed similar 63% detection endpoints in copies/assay for the different viral standards. The values for Ultrio almost reached the theoretical limitation of NAT sensitivity for HCV and HIV, but not for HBV. Conclusions The bdna 3.0 hybridisation assays may serve as a reference method for calibrating viral standards in copies/ml because the analytical sensitivities of the individual NAT blood screening assays on the different viral standards were similar (except for Ultrio HBV). For HIV and HCV the Chiron Ultrio assay reached the maximum achievable sensitivity, which may confirm the accurate absolute quantification in copies/ml by the bdna 3.0 assay.

2 Quantification of standards in SI units or calibration against WHO standards.error! Objects cannot be created Error! Objects cannot be created Error! Objects cannot be created The figure depicts the requirements for quantifying in SI units. The presence of an analytical method is necessary. In this study the Bayer Versant bdna 3.0 assays were evaluated on the ability to fulfill this requirement. The metrological levels show when which type of calibrator material is appropriate. Ideally level 1 should be reached. Lower levels cause less harmonisation of test results. Level 4 is always possible as first attempt to standardise testing. This requires a long-term available stable material. Secondary working standards may be needed. Then an analytical method is also required. The bdna assays include secondary calibrators which are traceable to the NIST Phosphor standard. The Phosphor standard in quantified in mol (SI unit). The quantification in copies/ml is within the accuracy of calibration on the Phosphor standard relating to SI units. (Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. M.L. Collins, J.J. Zayetti, B. Detmer et al. Anal. Biochem. 1995, 226: Quantification of HBV-DNA genotype A standard. Available HBV-DNA standards and their characterisation Eurohep standards for HBV-DNA were quantified in proficiency studies. Value assignment was done in Eurohep units/ml (aiming to be equal to copies/ml) WHO standard for HBV-DNA. The first standard was characterised in collaborative studies and a value in IU/ml was assigned. The WHO standard is a lyophilised 1:500 dilution of the EUROHEP genotype A standard. BQC HBV-DNA standards are calibrated against the EUROHEP and WHO standard and bdna 3.0 testing.

3 Quantification of HBV-DNA genotype A standard dilutions, expressed in undiluted standard. Assay average Ln (conc) stdev n low up Bayer bdna E E E E+09 Chiron bdna E E E E+09 Roche Ampl. Mon. 2.11E E E E+09 Sangtec Affig.VL 1.17E E E E+09 Roche Taqman 7.29E E E E+09 Artus RealArt HBV PCR 2.17E E E E+09 Digene HCS 1.63E E E E+09 Digene HCS Ultra 1.30E E E E+09 There is large consensus between the Roche HBV-DNA Amplicor Monitor 2.0 and Bayer Versant bdna 3.0 tests. The results of Sangtec Affigene VL, Digene HCS Ultra are not significantly different while Digene HCS was significantly lower. Roche Taqman confirmed the quantification in 2003 but in 2004 a lower value (5 times) was measured. Error! Objects cannot be created The quantification of the EUROHEP HBV-DNA standards is based on establishing a consensus value between quantitative testing (corrected on a clone traceable to the NIST Phosphor standard) and limiting dilution PCR testing. Both methods aim to quantify in copies/ml. The results varied from 2.2 to E9 copies/ml. By definition limiting dilution results will be equal to real value or lower (when the PCR efficiency is less than 100 %). The quantitative tests may over- or underestimate. In the 1997 proficiency study dilution series of BQC HBV-DNA genotype A standard and EUROHEP HBV- DNA genotype A standard were tested simultaneously in calibration experiments (1996, 1998) and proficiency testing (1997, 1999) using the Chiron bdna 1.0 assay. In 2008 both standards were tested 6-fold in the Bayer Versant bdna 3.0 assay. The WHO standard is a 1:500 dilution of the EUROHEP HBV-DNA genotype A standard. In 2001 WHO and BQC standard dilution series covering the dynamic range were tested multiple times in the Bayer Versant bdna 3.0 assay. Year copies/ml ln (copies/ml) Stdev N low up EUROHEP genotype A standard / WHO standard 1996/98-EH 3.89E E E E EH 3.74E E E E WHO 2.67E E E E+09 BQC genotype A standard 1996/ E E E E E E E E E E E E+09 The WHO standard quantification is multiplied by 500 to allow comparison to the EUROHEP calibrations. No correction was made for lyophilisation. The expert committee assigned a value of IU per vial or ml to the WHO standard (An international Collaborative study to establish a WHO International Standard for Hepatitis B virus DNA Nucleic Amplification Techniques. J. Saldanha, W.H. Gerhlich, P.N. Lelie, K.H. Heerman and A. Heath. Vox Sang. 2001, 80: 63-71). The overall value for the BQC standard is copies/ml ( ). We conclude one IU is equal to 5.33 copies. As the 2 nd WHO HBV-DNA standard is manufactured equally and from same source materials the conversion factor is also assumed for the 2 nd WHO HBV-DNA standard. The potencies between the EUROHEP and BQC HBV-DNA standards were 83% (bdna 1.0) and 73 % (bdna 3.0) while we found for the WHO standard 81 %.

4 Quantification of HIV-RNA genotype B standard. Available HIV-RNA standards and their characterisation 1 st and 2 nd WHO standard for HIV-RNA. In the collaborative study for establishing the WHO HIV-RNA standard both the 1 st and 2 nd WHO HIV-RNA and the BQC HIV-RNA standard were evaluated together. Using the bdna 2.0 measurements we calculated 0.49 copies is one IU for the 1 st WHO HIV-RNA standard and 0.64 copy is one IU for the 2 nd WHO HIV-RNA standard (An international collaborative study to establish the 1 st International Standard for HIV-1-RNA for use in Nucleic Acid-Based Techniques. H. Holmes, C. Davis, A. Heath, I. Hewlett and P.N. Lelie. J. Virol. Methods 2001, 92: ). The quantification in copies/ml is presented in the table below. Quantification of HIV-RNA genotype B standard dilutions, expressed in undiluted standard. Assay average Ln (conc) stdev n low up bdna E E E E+08 bdna E E E E+08 bdna E E E E+08 Abbott 1.95E E E E+08 NucliSens 2.40E E E E+08 Roche Mon.V E E E E+08 Roche Mon V1.0 mixed primers 1.53E E E E+08 Roche Mon. V E E E E+08 Roche Mon. V1.5 UltraSens 1.24E E E E+08 The biomerieux and Abbott assays are calibrated against the VQA standard causing a sgnificant differences in quantitation. Quantification of HCV-RNA genotype 1 standard. Available HCV-RNA standards and their characterisation Eurohep HCV-RNA genotype 1 and 3 standards for HCV-RNA were quantified in proficiency studies. Value assignment was done in geq/ml by testing bdna 1.0 (geq and copy are equivalent) 1 st WHO standard for HCV. The first standard was characterised in a collaborative study and values were assigned. The first and second WHO HCV-RNA was derived from the same HCV-RNA, a-hcv positive plasma pool. The third WHO HCV-RNA standard is derived from a HCV-RNA positive anti-hcv negative plasma pool BQC HCV-RNA genotype 1 standard is calibrated against Eurohep standard and the 1st WHO HCV-RNA standard. Quantification of HCV-RNA genotype 1 standard dilutions, expressed in undiluted standard. Assay average Ln (conc) stdev n low up bdna E E E E+06 bdna E E E E+07 bdna E E+01 4 Amplicor COBAS E E E E+06 Amplicor MWP E E E E+06 Calibration against WHO standard A HCV genotype 1 standard dilution was included in the WHO calibration study for secondary HCV-RNA reagents (Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. J. Saldanha, A. Heath, N. Lelie, G. Pisani, M. Nubling, M. Yu. Vox Sang. 2000;78(4):217-24). The preparation containing 2732 copies/ml was assigned a value of 1000 IU/ml. The conversion factor becomes 2.73 copies is one IU.

5 Comparison quantification BQC HCV-RNA genotype 1 standard to limiting dilution analysis Both BQC and WHO HCV-RNA standard dilution series were used for estimation of analytical sensitivity on blood screening assays. We calculated the 63 % hit rate and corrected this for the amplication input volume from 29 studies. To convert IU to copies 2.73 was used. Only the first and second WHO HCV- RNA standards were used. Both WHO standards are prepared from the same source and processed similar. We compared the WHO and BQC HCV-RNA standards in the unpaired student-t test. The populations did not present a significant difference. 95% Confidence Interval of the Difference Sig. (2- Mean Std. Error t df tailed) Difference Difference Lower Upper The distribution of 63 % hit rates reveals an asymptote at 1.0 copy input. This confirms the bdna quantification in copies/ml as well as the commutability to the WHO standard using 2.73 copies is one IU as conversion factor. The graph depicts the sorted copies input (n=15) copies input calc line WHO BQC case

6 Calibration HCV-RNA genotype standards. The other HCV-RNA genotypes were tested simultaneously against the BQC HCV-RNA genotype 1 standard in Bayer Versant 3.0 assay. This was done is two separate HCV-RNA genotype 1 standard. The standards include HCV-RNA genotype 2, 3, 4, 5, 6 and inactivated genotype 3a. To control the quantification by bdna 3.0 standard dilution panels were tested in Novartis Procleix Ultrio and Roche MPX. Using probit analysis the potencies between genotypes were calculated. Comparison Ultrio (n=24) and Roche MPX (n=12) by estimation potencies using parallel line probit analysis for each assay. Ultrio EFS/ARCBS MPX EFS genotype Estimate Lower Upper Estimate Lower Upper Conclusion calibration HCV standards The absolute quantification of the HCV-RNA genotype 1 standard is confirmed by limiting dilution analysis. The potency analysis on different genotypes is significantly different for genotype 3 vs 5 in both Roche MPX and Ultrio testing. Further research is needed to establish the correct quantification for these two genotypes. Origin of test results For quantification in bdna 3.0 longitudinal test results obtained in calibration experiments and proficiency testing were used. The limiting dilution analyses were done using literature data. We used the results of head-to-head comparisons between Novartis Procleix Ultrio and Roche MPX (Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201.Assal A, Barlet V, Deschaseaux M, Dupont I, Gallian P, Guitton C, Morel P, David B, De Micco P. Transfusion Nov 4 and Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Margaritis AR, Brown SM, Seed CR, Kiely P, D'Agostino B, Keller AJ. Transfusion Oct;47(10): )

Quantification of HBV, HCV genotype and HIV subtype panels

Quantification of HBV, HCV genotype and HIV subtype panels Quantification of HBV, HCV genotype and HIV subtype panels Harry van Drimmelen 1,2, Wim Quint 2, Nico Lelie 3 and the international NAT study group 1. Biologicals Quality Control, 2. DDL Diagnostic Laboratory,

More information

HBV-DNA reference panels

HBV-DNA reference panels HBV-DNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HBV-DNA panels

More information

HIV-RNA reference panels

HIV-RNA reference panels The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Overview HIV-RNA panels for sensitivity analysis...

More information

Calibration and stability of WHO and secondary viral standards

Calibration and stability of WHO and secondary viral standards Calibration and stability of WHO and secondary viral standards Nico Lelie, Harry van Drimmelen and the International NAT Study Group Facilities DDL Diagnostic Laboratories Outline Calibration of WHO and

More information

P0064 ViraQ HIV-1 Check 125 P0064

P0064 ViraQ HIV-1 Check 125 P0064 P0064 ViraQ HIV-1 Check 125 P0064 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use...

More information

P0141 HBV 1000 copies/ml genotype reference panel

P0141 HBV 1000 copies/ml genotype reference panel P0141 HBV 1000 copies/ml genotype reference panel P0141 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents

More information

P0069 ViraQ HBV Trend 25 P0069

P0069 ViraQ HBV Trend 25 P0069 P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3

More information

P0154 ViraQ HBV Trend 50 P0154

P0154 ViraQ HBV Trend 50 P0154 P0154 ViraQ HBV Trend 50 P0154 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3

More information

P0069 ViraQ HBV Trend 25 P0069

P0069 ViraQ HBV Trend 25 P0069 P0069 ViraQ HBV Trend 25 P0069 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3

More information

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control

Experience with Standardisation of Blood Virology NAT. Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Experience with Standardisation of Blood Virology NAT Clare Morris Division of Retrovirology National Institute for Biological Standards and Control Background of Blood Virology Standardisation In the

More information

Stability of native, lyophilized and inactivated standards

Stability of native, lyophilized and inactivated standards Stability of native, lyophilized and inactivated standards Harry van Drimmelen Bio Quality Control, Heiloo, Netherlands Satellite Meeting before IPFA-PEI 25 th Workshop Twenty-five Years Standardization

More information

P0063 ViraQ HCV Check 125 P0063

P0063 ViraQ HCV Check 125 P0063 P0063 ViraQ HCV Check 125 P0063 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3

More information

P0067 ViraQ HCV Trend 25 P0067

P0067 ViraQ HCV Trend 25 P0067 P0067 ViraQ HCV Trend 25 P0067 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended use... 3

More information

Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012

Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 Update from ISS on following EQA studies: ISS EQA Tri-NAT (HCV, HIV and HBV) 2012 ISS EQA NAT HBV 2012 ISS EQA NAT WNV 2012 SOGAT XXIV Ljubljana, 8-9 May 2013 2012 ISS EQAs for NAT ISS EQA Tri-NAT (HCV,

More information

P0064 ViraQ HIV-1 Check 125 P0064

P0064 ViraQ HIV-1 Check 125 P0064 P0064 ViraQ HIV-1 Check 125 P0064 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use...

More information

Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands

Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com

More information

Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands

Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands PRODUCT CATALOGUE Customer Service and Ordering Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 info@bioqcontrol.com www.bioqcontrol.com

More information

P0254 ViraQ Multi-Marker Check 125

P0254 ViraQ Multi-Marker Check 125 P0254 ViraQ Multi-Marker Check 125 P0254 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance P0254 ViraQ Multi-Marker Check

More information

P0063 ViraQ HCV Check 125 P0063

P0063 ViraQ HCV Check 125 P0063 P0063 ViraQ HCV Check 125 P0063 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended use... 3

More information

Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI

Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI Ergebnisse der Abfrage zu NAT-only positiven Befunden beim Blutspendescreening (NAT yield) Micha Nübling, PEI NAT for cellular blood components in Germany Definition of minimal NAT sensitivity limit (ID)

More information

John Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, April, 2011

John Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, April, 2011 John Saldanha Regulatory Requirements: Precision and Accuracy of Quantitative NAT Tests XXII SoGAT Meeting, 14 15 April, 2011 Istituto Superiore di Sanita (ISS), Rome, Italy 2 June 2011 page 1 2011 Roche

More information

Standardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI

Standardization: Calibration of. International Standards, reference preparations and working standards. Micha Nübling, PEI Standardization: Calibration of International Standards, reference preparations and working standards Micha Nübling, PEI Paul-Ehrlich-Institut Governmental Authority for biological medicinal products Blood

More information

Evaluation of run controls for cobas 6800 MPX and HEV assay

Evaluation of run controls for cobas 6800 MPX and HEV assay Evaluation of run controls for cobas 6800 MPX and HEV assay Marco Koppelman Head of Nucleic Acid testing (NAT) laboratory, National Screening laboratory of Sanquin (NSS) in the Netherlands Satellite Meeting

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

Hepatitis C Virus (RNA)A

Hepatitis C Virus (RNA)A Hepatitis C Virus (RNA)A 2012 EQA Programme Final Report QAV994112 (HCVRNA12A) Professor Jacques Izopet Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2012 A UKAS accredited

More information

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA.

Laboratory for Clinical and Biological Studies, University of Miami Miller School of Medicine, Miami, FL, USA. 000000 00000 0000 000 00 0 bdna () 00000 0000 000 00 0 Nuclisens () 000 00 0 000000 00000 0000 000 00 0 Amplicor () Comparison of Amplicor HIV- monitor Test, NucliSens HIV- QT and bdna Versant HIV RNA

More information

P0078 SeraQ ARCHITECT P0078

P0078 SeraQ ARCHITECT P0078 P0078 SeraQ ARCHITECT P0078 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key

More information

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)

Diagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves

More information

NAT / BLOOD SCREENING - PRODUCT RANGE

NAT / BLOOD SCREENING - PRODUCT RANGE NAT / BLOOD SCREENING - PRODUCT RANGE QC Sample Name Analytes Assay / Instrument Page QConnect TriScreen Roche cobas TaqScreen MPX Test, v 2.0 (s201) Roche cobas MPX Test (6800/8800) QConnect Grifols Ultrio

More information

P0180 SeraQ LIAISON P0180

P0180 SeraQ LIAISON P0180 0 P0180 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key to Symbols Used...

More information

Assays to Address Emerging Threats to Blood Safety

Assays to Address Emerging Threats to Blood Safety Assays to Address Emerging Threats to Blood Safety Jeffrey M. Linnen, Ph.D. Director, Product Development Gen-Probe Incorporated San Diego, CA The IPFA/PEI 17th Workshop on Surveillance and Screening of

More information

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia 1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples

More information

HBV PUBLIC HEALTH IMPLICATIONS

HBV PUBLIC HEALTH IMPLICATIONS جزايری دکتر سيد محمد آزمايشگاه ھپاتيت B -دانشکده بھداشت ويروس شناسی- گروه دانشگاه علوم پزشکی تھران کنگره ارتقا کيفيت- ١٣٩٢ HBV PUBLIC HEALTH IMPLICATIONS 2 billion people have been infected by HBV worldwide.

More information

WHO Parvovirus B19 Genotype Panel

WHO Parvovirus B19 Genotype Panel WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)

More information

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management

More information

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience

External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience External Quality Assessment Programmes (EQAPs) for blood-borne viruses: the Italian experience Giulio Pisani Biologicals Unit CRIVIB, ISS, Rome SOGAT XXII 14 th 15 th April 2011 - Istituto Superiore di

More information

HEV Assay Development Update

HEV Assay Development Update HEV Assay Development Update Jeffrey M. Linnen, Ph.D. Senior Director, Research & Development Hologic Gen-Probe, San Diego, California USA IPFA/PEI 20th International Workshop on Surveillance and Screening

More information

Evaluation of external NAT controls from two manufacturers

Evaluation of external NAT controls from two manufacturers Evaluation of external NAT controls from two manufacturers Aneta Kopacz, Institute of Hematology and Transfusion Medicine, Warsaw, Poland NAT and External QC in Poland (2018) SCREENING Regional Blood Transfusion

More information

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as

More information

Non-competitive Internal Control Concept for PCR-based Qualitative Assays

Non-competitive Internal Control Concept for PCR-based Qualitative Assays Christian O. Simon Roche Molecular Diagnostics Rotkreuz, CH Non-competitive Internal Control Concept for PCR-based Qualitative Assays 23 rd SoGAT Meeting, 16 th 17 th April, 2012, Vilnius, Lithuania Design

More information

HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center

HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized

More information

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015 EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 12 to 16 October 2015 WHO/BS/2015.2262 ENGLISH ONLY Collaborative Study to Evaluate the Proposed 5 th WHO International Standard for Hepatitis C Virus

More information

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2011 Collaborative Study to Evaluate the Proposed 3 rd WHO International Standard for Hepatitis B Virus (HBV) for Nucleic

More information

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE

DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut

More information

Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/

Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/ www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:

More information

Technical Bulletin No. 161

Technical Bulletin No. 161 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

Practical Aspects of Standardisation for a Global Controls Manufacturer

Practical Aspects of Standardisation for a Global Controls Manufacturer Practical Aspects of Standardisation for a Global Controls Manufacturer MRSA SoGAT Clinical Diagnostic Meeting NIBSC, UK June 25, 2008 Frank Opdam PhD, AcroMetrix Standardisation A fundamental goal of

More information

Results of the College of American Pathologists (CAP) Proficiency Program for CMV, EBV, and BKV Viral Load Testing

Results of the College of American Pathologists (CAP) Proficiency Program for CMV, EBV, and BKV Viral Load Testing 2009 College of American Pathologists. The College does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The College hereby authorizes

More information

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company

More information

B19 Virus EQA Programme Final Report QAV (B19DNA14)

B19 Virus EQA Programme Final Report QAV (B19DNA14) B19 Virus 2014 EQA Programme Final Report QAV034116 (B19DNA14) Prof. Hubert GM Niesters Scientific Expert on behalf of QCMD Report authorised by the QCMD Executive in July 2014 A UKAS accredited proficiency

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

The Food and Drug Administration (FDA) has

The Food and Drug Administration (FDA) has NAT Comparative analysis of triplex nucleic acid test assays in United States blood donors Susan L. Stramer, David E. Krysztof, Jaye P. Brodsky, Tracy A. Fickett, Benjamin Reynolds, Roger Y. Dodd, and

More information

Molecular Diagnosis Future Directions

Molecular Diagnosis Future Directions Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular

More information

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM

More information

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2018Oct26 1 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Viral Load Quality Assessment Program Summary

More information

CMV Diagnostic Strategies: Current and Future

CMV Diagnostic Strategies: Current and Future CMV Diagnostic Strategies: Current and Future Tony Mazzulli, MD, FRCPC, FACP Microbiologist-in-Chief Mount Sinai Hospital & University Health Network, Toronto Faculty/Presenter Disclosure Relationships

More information

NAT Screening of Blood Donations in NBC, TRCS

NAT Screening of Blood Donations in NBC, TRCS IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine

More information

Technical Bulletin No. 162

Technical Bulletin No. 162 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

WHO Prequalification of Diagnostics Programme PUBLIC REPORT WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version 2.0 (TaqMan 48) Number: PQDx 0126-046-00 Abstract The COBAS AmpliPrep/COBAS TaqMan

More information

Performance of an automated system for quantification of hepatitis C virus RNA

Performance of an automated system for quantification of hepatitis C virus RNA Journal of Virological Methods 86 (2000) 55 60 www.elsevier.com/locate/jviromet Performance of an automated system for quantification of hepatitis C virus RNA Anne Marie Roque Afonso a, *, Josiane Didier

More information

The use of QCMD proficiency testing panels in clinical virology.

The use of QCMD proficiency testing panels in clinical virology. The use of QCMD proficiency testing panels in clinical virology. Prof.dr. Bert Niesters Department of Medical Microbiology Division of Clinical Virology UMC Groningen Disease Disease Management Viral Load

More information

ORIGINAL ARTICLE /j x. Hospital, Blood Bank, Udine, Italy

ORIGINAL ARTICLE /j x. Hospital, Blood Bank, Udine, Italy ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01025.x Qualitative multiplex RT-PCR for simultaneous detection of hepatitis C virus and human immunodeficiency virus in plasma samples V. Adami 1,2, E. Falasca

More information

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens

NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens NRL EQAS for NAT: Assessing the variability and performance of molecular assays for clinical pathogens Vincini GA*, Cabuang LM, Land S, Best SJ NRL London, 12 January 2011 NRL EQAS for NAT HCV Genotyping

More information

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017

EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 WHO/BS/2017.2314 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 International Collaborative Study to Establish the 4 th WHO International Standard for HIV-1 NAT

More information

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)

More information

Update on the. Clinical Diagnostics. and. Blood Testing. Meetings of SoGAT. Micha Nübling, PEI.

Update on the. Clinical Diagnostics. and. Blood Testing. Meetings of SoGAT. Micha Nübling, PEI. Update on the www.pei.de Clinical Diagnostics and Blood Testing Meetings of SoGAT Micha Nübling, PEI SoGAT Since 1995: 22 SoGAT meetings (organized by NIBSC) 1-2 meetings/year (connected with IPFA workshop)

More information

Performance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0

Performance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0 Clinical Chemistry / EVALUATION OF QUANTITATIVE HEPATITIS C VIRUS ASSAY Performance Characteristics of the COBAS AMPLICOR Hepatitis C Virus MONITOR Test, Version 2.0 Maria Erali, MS, 1 Edward R. Ashwood,

More information

Instructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^

Instructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^ Page 1 of 5 Page 1 of 5, 97/656 WHO 1 st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) NIBSC code: 97/656 Instructions for Use (Version 3-14 th May 2003) Changes from previous

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion

More information

New HIV Tests and Algorithm: A change we can believe in

New HIV Tests and Algorithm: A change we can believe in New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be

More information

on the road to harmonisation?

on the road to harmonisation? on the road to harmonisation? Prof. Dr.med.Michael Spannagl Munich- Heart of? 1 O zapft is - Oktoberfest 1 Key facts Date: September - October (1 days) Location: Munich - Theresenwiese 6,3 Mio. Visitors

More information

Roche Molecular Biochemicals Application Note No. HP 1/1999

Roche Molecular Biochemicals Application Note No. HP 1/1999 Roche Molecular Biochemicals Application Note No. HP 1/1999 Nucleic Acid Purification High Pure Viral Nucleic Acid Kit High Pure 16 System Viral Nucleic Acid Kit Efficiency of Hepatitis C Virus sample

More information

In October 2005, the South African National Blood

In October 2005, the South African National Blood DONOR INFECTIOUS DISEASE TESTING Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk_3355

More information

Efficient Extraction of Virus DNA by NucliSens Extractor Allows Sensitive Detection of Hepatitis B Virus by PCR

Efficient Extraction of Virus DNA by NucliSens Extractor Allows Sensitive Detection of Hepatitis B Virus by PCR JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2001, p. 4339 4343 Vol. 39, No. 12 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.12.4339 4343.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.

More information

Received 19 April 2011/Returned for modification 6 June 2011/Accepted 13 June 2011

Received 19 April 2011/Returned for modification 6 June 2011/Accepted 13 June 2011 JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2011, p. 2899 2904 Vol. 49, No. 8 0095-1137/11/$12.00 doi:10.1128/jcm.00785-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative

More information

W ith an estimated million people worldwide

W ith an estimated million people worldwide 141 ORIGINAL ARTICLE Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan C-Y Dai,

More information

The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing

The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides

More information

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27

HIV Viral Load Quality Assessment Program Summary for Panel HIVVL 2017Oct27 1 The National Laboratory for HIV Reference Services is Accredited to ISO 15189 and ISO 17043 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology

More information

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR Real-Time (DNA) Real-time Exicycler 96 Rotor-Gene Q/6000 IU Mix1 Mix2 IU/μl IU/μl IU/μl IU/μl IU/μl IPC NTC C 1 Lot# 2 Freeze & thawing 1 MSDS: Material Safety Data Sheets (TaqMan Real-time ' FAM ' BHQ1

More information

Official Journal of the European Communities COMMISSION

Official Journal of the European Communities COMMISSION 16.5.2002 EN Official Journal of the European Communities L 131/17 COMMISSION COMMISSION DECISION of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under

More information

EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK

EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on

More information

QUANTITATIVE HIV RNA (VIRAL LOAD)

QUANTITATIVE HIV RNA (VIRAL LOAD) CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October

More information

Papers. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA

Papers. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA J Clin Pathol 1999;52:807 811 807 Papers Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical College Hospital, No 100, Shih-Chuan 1st Rd, Kaohsiung, Taiwan, Republic of China M-L

More information

HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS

HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS HEPATITIS C VIRUS GENOTYPING IN CHRONIC HEPATITIS C PATIENTS I. Qattan Centres for Hepatology, Royal Free & University College Medical School, London V. Emery Department of Virology, Royal Free & University

More information

Impact of multi-dye multiplex technology on testing algorithm

Impact of multi-dye multiplex technology on testing algorithm Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT

More information

on May 2, 2018 by guest

on May 2, 2018 by guest JCM Accepts, published online ahead of print on 5 September 2012 J. Clin. Microbiol. doi:10.1128/jcm.01221-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 Title: Ten

More information

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan System,

Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan System, Journal of Clinical Virology 38 (2007) 326 333 Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan System, Dorothea Sizmann,

More information

TECHNICAL CONSIDERATIONS FOR THE PERFORMANCE OF NUCLEIC ACID AMPLIFICATION TECHNOLOGY (NAT)

TECHNICAL CONSIDERATIONS FOR THE PERFORMANCE OF NUCLEIC ACID AMPLIFICATION TECHNOLOGY (NAT) TECHNICAL CONSIDERATIONS FOR THE PERFORMANCE OF NUCLEIC ACID AMPLIFICATION TECHNOLOGY (NAT) The NAT Task Force Group Michael Chudy 1, Indira Hewlett 2, John Saldanha 3, Celso Bianco 4, Andrew J. Conrad

More information

AccuSet HBV Worldwide Performance Panel

AccuSet HBV Worldwide Performance Panel PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples

More information

Evaluation of the new Abbott mplus feature: Impact on clinical laboratory efficiencies with Abbott RealTime HIV-1, HCV, HBV and CT/NG assays

Evaluation of the new Abbott mplus feature: Impact on clinical laboratory efficiencies with Abbott RealTime HIV-1, HCV, HBV and CT/NG assays JCM Accepts, published online ahead of print on 2 October 2013 J. Clin. Microbiol. doi:10.1128/jcm.01672-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 Evaluation

More information

HIV-1 Seroconversion Panel PRB975

HIV-1 Seroconversion Panel PRB975 Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,

More information

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays About the author Disclaimer EXECUTIVE SUMMARY Molecular diagnostic technologies Healthcare-associated infections Sexually transmitted HPVs HIV and hepatitis viruses Market outlook and forecasts Molecular

More information

Introduction: Table/Figure Descriptions:

Introduction: Table/Figure Descriptions: Introduction: We have completed the analysis of your HIV RNA Validation Study. The validation plan was designed to verify the installation of an unmodified FDA-approved HIV RNA assay into your laboratory.

More information

HIV-1 Seroconversion Panel PRB973

HIV-1 Seroconversion Panel PRB973 A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians

More information

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B CLINICAL MICROBIOLOGY REVIEWS, July 2007, p. 426 439 Vol. 20, No. 3 0893-8512/07/$08.00 0 doi:10.1128/cmr.00009-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Molecular Testing

More information

to be notified: all parties involved in the graduated plan procedure. Annexes

to be notified: all parties involved in the graduated plan procedure. Annexes Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells

More information

INTERNATIONAL WORKING GROUP ON THE STANDARDISATION OF GENOME AMPLIFICATION TECHNIQUES (SoGAT) FOR CLINICAL DIAGNOSTICS

INTERNATIONAL WORKING GROUP ON THE STANDARDISATION OF GENOME AMPLIFICATION TECHNIQUES (SoGAT) FOR CLINICAL DIAGNOSTICS INTERNATIONAL WORKING GROUP ON THE STANDARDISATION OF GENOME AMPLIFICATION TECHNIQUES (SoGAT) FOR CLINICAL DIAGNOSTICS SoGAT Clinical Diagnostics I, 24-25 June 2008 National Institute for Biological Standards

More information

QUANTITATIVE HIV RNA (VIRAL LOAD)

QUANTITATIVE HIV RNA (VIRAL LOAD) CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: January

More information